Market Cap 30.74B
Revenue (ttm) 5.15B
Net Income (ttm) 1.40B
EPS (ttm) N/A
PE Ratio 19.99
Forward PE 18.57
Profit Margin 27.22%
Debt to Equity Ratio 0.06
Volume 3,810,400
Avg Vol 1,594,464
Day's Range N/A - N/A
Shares Out 145.06M
Stochastic %K 41%
Beta 0.76
Analysts Sell
Price Target $239.36

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 858-836-5000
Address:
9001 Spectrum Center Boulevard, San Diego, United States
EmmaEmpie563
EmmaEmpie563 Aug. 8 at 4:53 PM
$CFG $RMD $AEE $KHC $ZTS Citizens Financial remains tied to banking and credit conditions, ResMed benefits from sleep-health demand, Ameren benefits from regulated utility investment, Kraft Heinz provides defensive food exposure, and Zoetis benefits from resilient animal-health demand. I'm watching rates, utility capex, and consumer spending.
0 · Reply
dario2580
dario2580 Aug. 7 at 11:27 PM
$RMD Strong demand for sleep-apnea devices📈
1 · Reply
1986iamwallstreet
1986iamwallstreet Aug. 7 at 2:13 PM
$RMD 🩸
0 · Reply
SBL71
SBL71 Aug. 7 at 12:56 PM
$RMD yup. Micks got a problem. The long dominant pap device is going to be an option in a bucket of choices for OSA patients and the doctors that treat them. Still a huge undiagnosed population for sure but the day is coming where pap might be a 3rd line treatment option.
0 · Reply
DonCorleone77
DonCorleone77 Aug. 7 at 1:16 AM
$CABO $MRVI $RMD $TXG $DBX AFTER-HOURS MOVERS: Currently Higher After Earnings: Doximity (DOCS) up 73.8% Atlassian (TEAM) up 32.9% Figs (FIGS) up 23.7% QuinStreet (QNST) up 27.9% Cloudflare (NET) up 16.2% Twilio (TWLO) up 17.0% Natera (NTRA) up 15.4% Akamai (AKAM) up 12.1% Onto Innovation (ONTO) up 13.0% Airbnb (ABNB) up 7.8% Instacart (CART) up 9.9% Currently Also Higher: DoubleVerify (DV) up 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15B Currently Lower After Earnings: Trade Desk (TTD) down 24.3% QuidelOrtho (QDEL) down 23.1% Xponential Fitness (XPOF) down 12.7% Cable One (CABO) down 9.5% Maravai Lifesciences (MRVI) down 7.2% ResMed (RMD) down 5.9% 10x Genomics (TXG) down 3.5%. Dropbox (DBX) down 6.5% Post Holdings (POST) down 2.6%
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 8:13 PM
$RMD Q4 '26 Earnings Results & Recap • Reported GAAP EPS of $2.65 up 2.32% YoY • Reported revenue of $1.46B up 8.58% YoY • Resmed Inc. is guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during fiscal year 2027, with a 10% quarterly dividend increase.
0 · Reply
Estimize
Estimize Aug. 6 at 3:01 PM
$RMD reports after the close, Estimize Consensus +0.05 EPS and +10.90M Revs compared to WS http://www.estimize.com/rmd/fq4-2026?utm_content
0 · Reply
macdub8
macdub8 Aug. 6 at 8:52 AM
$IXHL $RMD is up 22% over the past 6 weeks. Does the market know something we don't know?
1 · Reply
GabrielBarrett973
GabrielBarrett973 Aug. 5 at 5:32 AM
$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
0 · Reply
AnthonyCottrell683
AnthonyCottrell683 Aug. 3 at 2:47 PM
$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
0 · Reply
Latest News on RMD
ResMed price target lowered to $213 from $217 at Baird

2026-08-07T12:00:58.000Z - 1 day ago

ResMed price target lowered to $213 from $217 at Baird

RMD


ResMed price target lowered to $255 from $260 at KeyBanc

2026-08-07T10:31:20.000Z - 1 day ago

ResMed price target lowered to $255 from $260 at KeyBanc

RMD


ResMed reports Q4 EPS $2.95, consensus $2.89

2026-08-06T20:32:29.000Z - 2 days ago

ResMed reports Q4 EPS $2.95, consensus $2.89

RMD


ResMed increases quarterly dividend 10% to 66c per quarter

2026-08-06T20:32:11.000Z - 2 days ago

ResMed increases quarterly dividend 10% to 66c per quarter

RMD


ResMed Earnings Call Transcript: Q4 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

ResMed Earnings Call Transcript: Q4 2026


ResMed Earnings release: Q4 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

ResMed Earnings release: Q4 2026


ResMed Slides: Q4 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

ResMed Slides: Q4 2026


ResMed price target lowered to $220 from $235 at Mizuho

2026-07-15T11:32:02.000Z - 24 days ago

ResMed price target lowered to $220 from $235 at Mizuho

RMD


ResMed downgraded to Neutral from Buy at Citi

2026-07-12T23:20:07.000Z - 27 days ago

ResMed downgraded to Neutral from Buy at Citi

RMD


ResMed price target lowered to $225 from $240 at Jefferies

2026-07-10T13:10:28.000Z - 4 weeks ago

ResMed price target lowered to $225 from $240 at Jefferies

RMD


ResMed price target lowered to $276 from $321 at RBC Capital

2026-07-08T11:45:32.000Z - 4 weeks ago

ResMed price target lowered to $276 from $321 at RBC Capital

RMD


ResMed price target lowered to $225 from $227 at Wells Fargo

2026-07-08T10:25:21.000Z - 4 weeks ago

ResMed price target lowered to $225 from $227 at Wells Fargo

RMD


ResMed to sell software business MatrixCare for $490 million

Jul 7, 2026, 6:07 PM EDT - 4 weeks ago

ResMed to sell software business MatrixCare for $490 million

RMD


Resmed Announces Agreement to Sell MatrixCare Business

Jul 7, 2026, 4:30 PM EDT - 4 weeks ago

Resmed Announces Agreement to Sell MatrixCare Business

RMD


ResMed Slides: Divestiture of MatrixCare presentation

Jul 7, 2026, 7:00 AM EDT - 4 weeks ago

ResMed Slides: Divestiture of MatrixCare presentation


ResMed added to APAC Conviction List at Goldman Sachs

2026-07-01T23:15:24.000Z - 5 weeks ago

ResMed added to APAC Conviction List at Goldman Sachs

RMD


ResMed price target lowered to $266 from $290 at KeyBanc

2026-06-22T09:45:57.000Z - 6 weeks ago

ResMed price target lowered to $266 from $290 at KeyBanc

RMD


ResMed beats quarterly profit estimates, names new CFO

Apr 30, 2026, 6:21 PM EDT - 3 months ago

ResMed beats quarterly profit estimates, names new CFO

RMD


ResMed Earnings Call Transcript: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

ResMed Earnings Call Transcript: Q3 2026


ResMed Earnings release: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

ResMed Earnings release: Q3 2026


ResMed Slides: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

ResMed Slides: Q3 2026


ResMed Quarterly report: Q3 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

ResMed Quarterly report: Q3 2026


ResMed At $250: Missed Opportunity Or A Trap In The Making?

Feb 25, 2026, 12:56 PM EST - 5 months ago

ResMed At $250: Missed Opportunity Or A Trap In The Making?

RMD


ResMed Earnings Call Transcript: Q2 2026

Jan 29, 2026, 4:30 PM EST - 6 months ago

ResMed Earnings Call Transcript: Q2 2026


ResMed Quarterly report: Q2 2026

Jan 29, 2026, 4:30 PM EST - 6 months ago

ResMed Quarterly report: Q2 2026


ResMed Earnings release: Q2 2026

Jan 29, 2026, 4:30 PM EST - 6 months ago

ResMed Earnings release: Q2 2026


ResMed Slides: Q2 2026

Jan 29, 2026, 4:30 PM EST - 6 months ago

ResMed Slides: Q2 2026


ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

ResMed Transcript: 44th Annual J.P. Morgan Healthcare Conference


ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

ResMed Slides: 44th Annual J.P. Morgan Healthcare Conference


IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 9 months ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX RMD


ResMed Transcript: AGM 2025

Nov 19, 2025, 6:00 PM EST - 9 months ago

ResMed Transcript: AGM 2025


ResMed Earnings Call Transcript: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 10 months ago

ResMed Earnings Call Transcript: Q1 2026


ResMed Quarterly report: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 10 months ago

ResMed Quarterly report: Q1 2026


ResMed Earnings release: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 10 months ago

ResMed Earnings release: Q1 2026


ResMed Slides: Q1 2026

Oct 30, 2025, 4:30 PM EDT - 10 months ago

ResMed Slides: Q1 2026


ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 11 months ago

ResMed Proxy statement: Proxy Filing


ResMed Proxy statement: Proxy Filing

Oct 2, 2025, 8:00 AM EDT - 11 months ago

ResMed Proxy statement: Proxy Filing


ResMed Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 11 months ago

ResMed Slides: Corporate Presentation


ResMed Slides: Sustainability Presentation

Sep 12, 2025, 7:00 AM EDT - 11 months ago

ResMed Slides: Sustainability Presentation


ResMed Earnings Call Transcript: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q4 2025


ResMed Annual report: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Annual report: Q4 2025


ResMed Earnings release: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q4 2025


ResMed Slides: Q4 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q4 2025


Spot Outliers Like ResMed Early with Money Flows

Jul 30, 2025, 6:08 AM EDT - 1 year ago

Spot Outliers Like ResMed Early with Money Flows

RMD


Resmed Acquires VirtuOx

May 1, 2025, 9:00 AM EDT - 1 year ago

Resmed Acquires VirtuOx

RMD


ResMed Earnings Call Transcript: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings Call Transcript: Q3 2025


ResMed Quarterly report: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Quarterly report: Q3 2025


ResMed Earnings release: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Earnings release: Q3 2025


ResMed Slides: Q3 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

ResMed Slides: Q3 2025


Jan De Witte joins GHO Capital as Operating Partner

Feb 11, 2025, 4:30 AM EST - 1 year ago

Jan De Witte joins GHO Capital as Operating Partner

IART RMD


ResMed Earnings Call Transcript: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings Call Transcript: Q2 2025


ResMed Earnings release: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Earnings release: Q2 2025


ResMed Quarterly report: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Quarterly report: Q2 2025


ResMed Slides: Q2 2025

Jan 30, 2025, 4:30 PM EST - 1 year ago

ResMed Slides: Q2 2025


ResMed Slides: FY 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

ResMed Slides: FY 2025


EmmaEmpie563
EmmaEmpie563 Aug. 8 at 4:53 PM
$CFG $RMD $AEE $KHC $ZTS Citizens Financial remains tied to banking and credit conditions, ResMed benefits from sleep-health demand, Ameren benefits from regulated utility investment, Kraft Heinz provides defensive food exposure, and Zoetis benefits from resilient animal-health demand. I'm watching rates, utility capex, and consumer spending.
0 · Reply
dario2580
dario2580 Aug. 7 at 11:27 PM
$RMD Strong demand for sleep-apnea devices📈
1 · Reply
1986iamwallstreet
1986iamwallstreet Aug. 7 at 2:13 PM
$RMD 🩸
0 · Reply
SBL71
SBL71 Aug. 7 at 12:56 PM
$RMD yup. Micks got a problem. The long dominant pap device is going to be an option in a bucket of choices for OSA patients and the doctors that treat them. Still a huge undiagnosed population for sure but the day is coming where pap might be a 3rd line treatment option.
0 · Reply
DonCorleone77
DonCorleone77 Aug. 7 at 1:16 AM
$CABO $MRVI $RMD $TXG $DBX AFTER-HOURS MOVERS: Currently Higher After Earnings: Doximity (DOCS) up 73.8% Atlassian (TEAM) up 32.9% Figs (FIGS) up 23.7% QuinStreet (QNST) up 27.9% Cloudflare (NET) up 16.2% Twilio (TWLO) up 17.0% Natera (NTRA) up 15.4% Akamai (AKAM) up 12.1% Onto Innovation (ONTO) up 13.0% Airbnb (ABNB) up 7.8% Instacart (CART) up 9.9% Currently Also Higher: DoubleVerify (DV) up 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15B Currently Lower After Earnings: Trade Desk (TTD) down 24.3% QuidelOrtho (QDEL) down 23.1% Xponential Fitness (XPOF) down 12.7% Cable One (CABO) down 9.5% Maravai Lifesciences (MRVI) down 7.2% ResMed (RMD) down 5.9% 10x Genomics (TXG) down 3.5%. Dropbox (DBX) down 6.5% Post Holdings (POST) down 2.6%
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 8:13 PM
$RMD Q4 '26 Earnings Results & Recap • Reported GAAP EPS of $2.65 up 2.32% YoY • Reported revenue of $1.46B up 8.58% YoY • Resmed Inc. is guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during fiscal year 2027, with a 10% quarterly dividend increase.
0 · Reply
Estimize
Estimize Aug. 6 at 3:01 PM
$RMD reports after the close, Estimize Consensus +0.05 EPS and +10.90M Revs compared to WS http://www.estimize.com/rmd/fq4-2026?utm_content
0 · Reply
macdub8
macdub8 Aug. 6 at 8:52 AM
$IXHL $RMD is up 22% over the past 6 weeks. Does the market know something we don't know?
1 · Reply
GabrielBarrett973
GabrielBarrett973 Aug. 5 at 5:32 AM
$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
0 · Reply
AnthonyCottrell683
AnthonyCottrell683 Aug. 3 at 2:47 PM
$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
0 · Reply
CaptainAmrica
CaptainAmrica Jul. 30 at 7:52 PM
$RMD $UMC $CRCL Initiated...
0 · Reply
danielte
danielte Jul. 30 at 8:47 AM
$RMD Volume Confirmation: Volume spiked to 5.37 million shares, well above recent consolidation averages, validating strong institutional accumulation on the move. Chart Pattern & Trend: On the daily chart, RMD spent the past several months in a primary downtrend, falling from peak levels near $280.00 down to a multi-month low of ~$186.00 in late June 2026. However, the stock recently completed a double-bottom reversal structure between $186.00 and $190.00 and has started carving out a series of higher highs and higher lows. Verdict: Viable Long Opportunity. RMD presents an attractive risk/reward trade setup as technical momentum turns bullish while the fundamental valuation remains discounted relative to historical norms.
0 · Reply
DanteValerian
DanteValerian Jul. 29 at 3:18 PM
$RMD keeps on rising after spending two weeks in the institutional accumulation zone. It's good knowing what the Financial Industry's Insiders are planning (ahead of time) $SPX $SPY $QQQ
0 · Reply
veryboredXYZ
veryboredXYZ Jul. 29 at 1:06 PM
$RMD 240 eoy
1 · Reply
DanteValerian
DanteValerian Jul. 28 at 2:28 PM
$RMD is surging nicely now, after two weeks of sloppy accumulation by the institutional insiders. We talked about RMD being a target for Financial Industry Insider Accumulation 2 - 3 weeks ago. Pretty sloppy as expected, but the low was where the Insiders' buy orders were waiting.
0 · Reply
OnlyFibs
OnlyFibs Jul. 21 at 2:37 AM
As a digital health pioneer scaling out-of-hospital software solutions and sleep apnea treatment ecosystems, $RMD combines robust cash generation with aggressive options accumulation. The options tape is showing active institutional sweep activity hitting the Ask on August call strikes like the $210 and $220 calls, signaling that smart money expects a sharp trend expansion. 🐂🎯 Bull Key Levels: Need to see a clean push through $200.00 to ignite fresh buying volume and trap late short sellers. 🐂🔥 Bear Key Levels: If the $192.00 level fails to hold, expect the price to consolidate further within the broader channel range. 🐻⚠️ Take Profit Targets: $212.00 / $222.00. 💰💸 #hovdid #rmd #smartmoney #stocks #optionsflow
1 · Reply
theresilienttrader
theresilienttrader Jul. 18 at 3:04 PM
$RMD After digging into ResMed ($RMD), I think the market may be underestimating one structural risk. It's not Philips. It's not pricing pressure. It's GLP-1 drugs. If fewer people develop severe sleep apnea because of sustained weight loss, that's fewer future CPAP customers and fewer years of recurring supply revenue. The installed base looks solid today, but the future patient funnel could be getting smaller. In this week's Resilient Trader Trade Idea, I break down the thesis and the defined-risk bear put spread I'm using to express it. $RMD $LLY $NVO https://www.theresilienttrader.com/p/the-silent-threat-to-resmed-rmd
1 · Reply
veryboredXYZ
veryboredXYZ Jul. 16 at 3:20 PM
$RMD opened a long position
0 · Reply
ParkerTradesX
ParkerTradesX Jul. 14 at 2:16 PM
The broader market maintains historically elevated metrics, with the S&P 500 average P/E ratio tracking near 25.6. High-conviction stock picking requires isolating relative value. The following assets present compelling alternative valuation structures: $ZTS P/E 12.51x $RMD 19.6x $NFLX 23.22x $PGR 11.69x $KNSL 14.92x BRO 19.22x CME 19.33x If you want to see the high-conviction stocks I’m watching, my full portfolio, and every trade I make… Head to my profile.
0 · Reply
stockro1
stockro1 Jul. 13 at 2:44 PM
$IXHL $RMD still find this interesting given Goldman Sachs continued presence on the L2…https://www.gurufocus.com/news/8941991/resmed-rmd-added-to-goldman-sachs-apac-conviction-list
0 · Reply
SBL71
SBL71 Jul. 13 at 11:50 AM
$RMD Apnimed IPO could be happening soon. It’s getting closer.
1 · Reply
jjjetplane
jjjetplane Jul. 10 at 7:28 PM
Doubled $MSFT and $NVDA positions today. Started $PODD and $RMD
0 · Reply